NOVA EYE MEDICAL LIMITED Financials Nova Eye Medical Limited
Equities
EYE
AU0000094252
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 AUD | 0.00% |
|
-10.71% | +4.17% |
| Mar. 15 | Nova Eye Medical Completes Retail Entitlement Offer | MT |
| Feb. 22 | Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: June | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 76.11 | 26.93 | 50.44 | 57.21 | - | - |
| Enterprise Value (EV) 1 | 75.82 | 20.88 | 43.02 | 51.11 | 52.26 | 50.56 |
| P/E ratio | -13.2 x | -3.57 x | -2.7 x | -5.97 x | -20.2 x | 250 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.93 x | 2.01 x | 2.96 x | 2.59 x | 1.82 x | 1.34 x |
| EV / Revenue | 0.93 x | 1.56 x | 2.53 x | 2.31 x | 1.66 x | 1.19 x |
| EV / EBITDA | -73.8 x | -3.28 x | -4.95 x | -7.69 x | -36 x | 10.8 x |
| EV / FCF | -15.4 x | -3.11 x | -5.64 x | -6.27 x | -13.8 x | 24.1 x |
| FCF Yield | -6.51% | -32.2% | -17.7% | -15.9% | -7.27% | 4.15% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 143,601 | 145,580 | 190,328 | 228,823 | - | - |
| Reference price 2 | 0.5300 | 0.1850 | 0.2650 | 0.2500 | 0.2500 | 0.2500 |
| Announcement Date | 8/28/19 | 8/26/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 81.64 | - | - | 13.38 | 17.02 | 22.1 | 31.4 | 42.6 |
| EBITDA 1 | -1.027 | - | - | -6.371 | -8.692 | -6.65 | -1.45 | 4.7 |
| EBIT 1 | -5.038 | - | - | -8.182 | -10.99 | -8.9 | -3.5 | 2.65 |
| Operating Margin | -6.17% | - | - | -61.16% | -64.55% | -40.27% | -11.15% | 6.22% |
| Earnings before Tax (EBT) 1 | -5.656 | - | - | -8.246 | -17 | -8.8 | -3.4 | 2.75 |
| Net income 1 | -5.773 | 35.65 | -4.356 | -7.496 | -15.29 | -8.55 | -3.15 | 2.7 |
| Net margin | -7.07% | - | - | -56.03% | -89.83% | -38.69% | -10.03% | 6.34% |
| EPS 2 | -0.0402 | - | - | -0.0518 | -0.0981 | -0.0418 | -0.0124 | 0.001000 |
| Free Cash Flow 1 | -4.933 | - | - | -6.721 | -7.624 | -8.15 | -3.8 | 2.1 |
| FCF margin | -6.04% | - | - | -50.24% | -44.78% | -36.88% | -12.1% | 4.93% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 44.68% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 77.78% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/28/19 | 8/28/20 | 8/18/21 | 8/26/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2024 S1 |
|---|---|---|
| Net sales 1 | 41.8 | 10.14 |
| EBITDA 1 | -0.1 | -4.184 |
| EBIT | -2.803 | - |
| Operating Margin | -6.71% | - |
| Earnings before Tax (EBT) | -2.933 | - |
| Net income 1 | -2.7 | -5.625 |
| Net margin | -6.46% | -55.48% |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 2/20/20 | 2/22/24 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 0.29 | - | - | 6.06 | 7.42 | 6.1 | 4.95 | 6.65 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -4.93 | - | - | -6.72 | -7.62 | -8.15 | -3.8 | 2.1 |
| ROE (net income / shareholders' equity) | -8.13% | - | - | -22.8% | -57.1% | -39.5% | -11.8% | 1% |
| ROA (Net income/ Total Assets) | -5.68% | - | - | -19.1% | -45.7% | -40.2% | -17.7% | 20.1% |
| Assets 1 | 101.7 | - | - | 39.31 | 33.49 | 21.27 | 17.8 | 13.43 |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | - | -0.0300 | -0.0100 | 0.0300 |
| Capex 1 | 0.73 | - | - | 0.13 | 0.26 | 1 | 1.25 | 1.25 |
| Capex / Sales | 0.89% | - | - | 1% | 1.54% | 4.52% | 3.98% | 2.93% |
| Announcement Date | 8/28/19 | 8/28/20 | 8/18/21 | 8/26/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.25
AUD
Average target price
0.52
AUD
Spread / Average Target
+108.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.17% | 38.1M | |
| +7.87% | 219B | |
| +11.83% | 192B | |
| +18.87% | 142B | |
| +30.03% | 111B | |
| +2.32% | 65.32B | |
| +14.15% | 52.45B | |
| +2.68% | 49.8B | |
| +6.60% | 43.43B | |
| +1.85% | 35.95B |
- Stock Market
- Equities
- EYE Stock
- Financials Nova Eye Medical Limited
